Archive for April, 2018

$NSPR Regulatory Approval, Reimbursement in Vietnam CGuard EPS™ and MGuard™

InspireMD, Inc. (NYSE AMER: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has received regulatory approval, and has initiated commercialization of its CGuard™ Embolic Prevention System (EPS) and MGuard Prime™ in Vietnam.  Both of these devices utilize the company’s patented MicroNet™ technology.

“Our ability to initiate commercialization for both of the company’s devices was due to our capability to coordinate getting three key elements in place concurrently and quickly. Specifically, we secured regulatory approval, a valid import license and product reimbursement, all of which come from Vietnam’s Department of Medical Equipment and Health Works (DMEHW), a unit of the Ministry of Health (MOH). Part of this effort was coordinated by DO GIA, our recently appointed distributor in Vietnam. DO GIA has an established distribution network across Vietnam that covers both physicians, clinics and hospitals. With a population of over 100 million people, Vietnam represents another important step forward in our focused expansion across Asia,” commented Agustin Gago, Chief Commercial Officer of InspireMD.

CGuard™ EPS is a carotid embolic protection system that is designed to deliver the company’s self-expanding stent wrapped in the company’s proprietary MicroNet™ technology to the carotid arteries using a rapid exchange delivery system to prevent embolic events that can lead to stroke. The MGuard Prime™ coronary stent system consists of the company’s coronary balloon expandable stent wrapped with MicroNet™ pre-mounted on a rapid exchange balloon catheter, that prevents embolic events in the heart that can result in myocardial infarction, heart failure and even death. Both products are now being sold in a variety of markets across Europe, Middle East, Asia and Latin America.

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MicroNet™ technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.

InspireMD intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard™), neurovascular, and peripheral artery procedures. InspireMD’s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS.

Forward-looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Investor Contacts:

InspireMD, Inc.

Craig Shore

Chief Financial Officer

Phone: 1-888-776-6804 FREE

Email: craigs@inspiremd.com   

Crescendo Communications, LLC

David Waldman

Phone: (212) 671-1021

Email: NSPR@crescendo-ir.com
Monday, April 30th, 2018 Uncategorized Comments Off on $NSPR Regulatory Approval, Reimbursement in Vietnam CGuard EPS™ and MGuard™

$ATOS Approval from Swedish Medical Products Agency for Endoxifen Study

Study’s Endpoints Are Changes in Mammographic Breast Density, Tolerability, and Safety

SEATTLE, April 30, 2018 — Atossa Genetics Inc. (Nasdaq:ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, announced today that it has received approval from the Swedish Medical Products Agency (MPA) to conduct a Phase 2 Study of its proprietary topical Endoxifen for the treatment of women with mammographic breast density, or MBD. Studies by others have shown that a reduction in MBD reduces the risk of developing breast cancer and may potentially improve the accuracy of mammography in finding cancer.

The Phase 2 study will be conducted at Stockholm South General Hospital in Sweden and will be led by principal investigator Dr. Per Hall, MD, Ph.D., Head of the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet. Atossa plans to open the study for enrollment this quarter.

The primary endpoint is individual change in MBD, which will be measured after three and six months of entering the study, and the secondary endpoints are safety and tolerability. Ninety participants will be randomized to one of three groups (one placebo group and two groups on different doses of topical Endoxifen) with 30 participants per group. The objective of the study is to determine the effect size of breast density between the topical and active groups, which will permit sample size calculations in a future Phase III study.

“Dr. Hall is widely regarded as a leading researcher in the field of breast cancer and prevention. He is heading the unique KARMA (Karolinska Mammography Project for Risk Prediction of Breast Cancer) Cohort, including over 70,000 women, which is regarded as the best characterized breast cancer cohort in the world and serves as a resource for studies about breast cancer risk assessment and prevention, and the Karisma Intervention Study, which is studying the change in MBD in women taking various doses of oral tamoxifen. We are honored to be working with Dr. Hall and his colleagues on our Phase 2 study of MBD as their unique experience and qualifications are simply unmatched anywhere in the world,” said Dr. Steven C. Quay, CEO and President of Atossa.

Atossa’s Proprietary Endoxifen

Endoxifen is an active metabolite of tamoxifen. Tamoxifen is an FDA-approved drug to prevent new breast cancer as well as recurrent breast cancer in breast cancer patients. Tamoxifen itself must be broken down by the liver into active compounds (metabolites), of which Endoxifen is the most active. Atossa has completed a comprehensive Phase 1 clinical study using both a topical and an oral formulation of Endoxifen. Preliminary results from the topical arm of the study indicated that the topical formulation was safe, well tolerated and that topical Endoxifen crossed the skin barrier in a dose-dependent fashion.

Topical Endoxifen Opportunities

Atossa is developing its proprietary topical Endoxifen to reduce MBD, which has been shown in studies conducted by others to be an independent risk factor for developing breast cancer. To date, 30 U.S. states require that findings of MBD be directly communicated to the patient. Although oral tamoxifen has been shown to reduce MBD, the benefit-risk ratio is generally not acceptable to most physicians and their patients. For example, it is estimated that only ~ 2% of women at high-risk of developing breast cancer, including those with MBD, take oral tamoxifen to prevent breast cancer because of the risks of, or actual side-effects of, oral tamoxifen.

Atossa is also developing topical Endoxifen for a condition in men called gynecomastia, which is male breast enlargement, which affects 25% of men between the ages of 50-69.  Atossa has commenced a Phase 1 study in men using topical Endoxifen, which it plans to fully-enroll this quarter.

Oral Endoxifen Opportunity

Approximately one million breast cancer survivors take oral tamoxifen annually; however, up to half of them do not properly metabolize tamoxifen and do not have desired levels of Endoxifen (meaning they are “refractory”). Low Endoxifen levels in breast cancer patients taking oral tamoxifen are associated with an increased risk of recurrence or the development of new breast tumors. Providing oral Endoxifen directly to the patient without having to be metabolized by the liver may help to address this problem.

Based on the number of women at high-risk of developing breast cancer and the number of patients who have survived breast cancer but are refractory to tamoxifen, Atossa estimates that the potential markets for its proprietary oral and topical formulations of Endoxifen could each potentially exceed $1 billion in annual sales.

The Medical Products Agency

The Medical Products Agency is the government agency in Sweden responsible for regulation and surveillance of the development, manufacturing and sale of medicinal drugs, medical devices and cosmetics.

The Swedish Medical Products Agency is one of the leading regulatory authorities in the EU. During the last five years, the Swedish MPA has been among the top three agencies in Europe, counting the number of approval processes managed for central (i.e. European) approvals of medicines. The Swedish MPA also has strong representation in more than 110 working groups and committees in the scope of the Heads of Medicines Agencies (HMA) and European Medicines Agency (EMA) for regulation of medical products in Europe.

The Medical Products Agency is a government body under the aegis of the Swedish Ministry of Health and Social Affairs. Its operations are largely financed through fees. Approximately 750 people work at the agency; most are pharmacists and doctors.

Breast Cancer Statistics

The American Cancer Society (ACS) estimates that approximately 268,000 women will be diagnosed with breast cancer in the United States this year and that approximately 41,000 will die from the disease. It is the second leading cause of cancer death in American women. Although about 100 times less common than women, breast cancer also affects men. The ACS estimates that in 2018 2,550 new cases of invasive breast cancer will be diagnosed in men; and 480 men will die from breast cancer.

About Stockholm South General Hospital

Stockholm South General Hospital is one of the largest hospitals in Sweden, offering care to more than two million Stockholmers. It is one of four hospitals collaborating with Karolinska on the KARMA project. For more information, please visit http://www.sodersjukhuset.se/Functions/InEnglish/.

About Karolinska Institutet

Karolinska Institutet, located in Stockholm, Sweden, is one of the world’s foremost medical universities. Its vision is to make a significant contribution to the improvement of human health; its mission is to conduct research and education and to interact with the community. As a university, KI is Sweden’s single largest center of medical academic research and offers the country’s widest range of medical courses and programs. The Nobel Assembly at Karolinska Institutet selects the Nobel laureates in Physiology or Medicine. For more information, please visit www.ki.se/en and www.KARMAstudy.org.

About Atossa Genetics

Atossa Genetics Inc. is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit www.atossagenetics.com.

Forward-Looking Statements

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with any variation between preliminary and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa’s products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others with respect to fulvestrant, such as patent rights, potential market sizes for Atossa’s drugs under development and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Atossa Genetics Company Contact:

Atossa Genetics Inc.
Kyle Guse
CFO and General Counsel
(O) 866 893-4927
kyle.guse@atossagenetics.com

Investor Relations Contact:

Scott Gordon
CoreIR
377 Oak Street
Concourse 2
Garden City, NY 11530
Office: 516 222-2560
scottg@CoreIR.com

Monday, April 30th, 2018 Uncategorized Comments Off on $ATOS Approval from Swedish Medical Products Agency for Endoxifen Study

$NETE Multi-Channel Platform Offering Simplified End-to-End Payment Processing

April 30, 2018

  • Netevia offers full integration with all major platforms, with the possibility of expanding compatibility in the future
  • Instant onboarding, three-hour funding time, enhanced security and payment conversion optimization are among platform’s main features
  • Platform further solidifies Net Element’s position as a leading provider of innovative and disruptive payment solutions

Currently at the strongest financial position in its history after a highly successful 2017, global technology and value-added solutions group Net Element, Inc. (NASDAQ: NETE) is moving forward with its goal of simplifying global commerce and payments through proprietary multi-channel platform Netevia (http://nnw.fm/4xOGd).

Launched earlier this year, Netevia is a future-ready multi-channel platform designed to serve as blueprint and set of tools for global commerce and monetization by simplifying and connecting payment across different sales channels via a single integration point. Offering end-to-end payment processing services through easy APIs, the platform was designed by developers with developers in mind, according to Net Element Chief Technology Officer Andrey Krotov, and includes SDKs and sandbox for testing, offering all the building blocks and features needed to integrate payment acceptance into virtually any e-commerce solution.

Netevia is fully integrated with all major platforms, allowing vendors to accept a wide range of payment methods in multiple currencies on any device. The platform is highly flexible, being continuously adjusted and expanded so as to enable the addition of new features and services as payment needs change. Recent or still in development features include free processing in exchange for data, integration with smart terminals for card present sales, gift card solutions to drive increased sales and repeat business and, last but not least, cryptocurrency payment processing for multi-channel transactions.

In addition to flexibility and vast platform compatibility, Netevia offers merchants multiple valuable features, including instant onboarding, same day settlement and funding and payment conversion optimization that can help vendors reach 99.2 percent conversion rates and higher revenues – everything available for a highly competitive price. The latest service, added to the platform in early April 2018, was Fast Pass Funding, which allows eligible merchants to receive funding in as little as three hours during business days, a massive improvement to the previous 12- to 24- hour waiting period. Netevia also provides state-of-the-art security and fraud prevention services via more than 150 risk monitoring filters, vaulting, tokenization and point-to-point encryption.

With a focus on supporting electronic payments acceptance in a multi-channel environment, including point-of-sale, e-commerce and mobile devices, Net Element is uniquely positioned to disrupt the payment processing industry. The group is currently in its best financial situation in history, after a successful year 2017 marked by an increase in revenues ($60.1 million from $54.3 million in 2016), an improved balance sheet of $11.3 million cash in hand and financial debt of $7 million at the end of the year, and a wide array of partnerships geared toward simplifying payments across multiple sales channels worldwide.

Net Element will continue to embrace and develop innovative payment processing technologies in its efforts to capitalize on the fast-growing e-commerce market, which is expected to more than double its value over the next three years and reach $4.88 trillion by 2021, from $2.3 trillion in 2017 (http://nnw.fm/A3xNh).

For more information, visit the company’s website at www.NetElement.com

More from NetworkNewsWire

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Monday, April 30th, 2018 Uncategorized Comments Off on $NETE Multi-Channel Platform Offering Simplified End-to-End Payment Processing

$CIIX Cryptocurrency Trading Courses via Bitcoin Trading Academy, Starting June 9

SAN GABRIEL, California, April 30, 2018 /PRNewswire/ —

ChineseInvestors.com Inc. (OTCQB: CIIX)(“CIIX” or the “Company”), the premier financial information website for Chinese-speaking investors, today announces new cryptocurrency and trading courses offered through its newly established Bitcoin Trading Academy LLC beginning in June 2018.

The Bitcoin Trading Academys course offering will include:

Bitcoin Trading 101: Students will gain basic knowledge about Bitcoin including how to open trading accounts on the most commonly held cryptocurrency trading platforms how to set up a cryptocurrency wallet. In addition, students will be educated on Bitcoin Futures trading strategies, both long and short, how to use Bitcoin Futures to properly hedge one’s Bitcoin portfolio, and how to properly use beginner-friendly trading techniques trading techniques such as Candlesticks and Moving Averages, among other key metrics that top financial analysts use in trading assets.

Bitcoin Trading 201: The second course in the program will focus on coins such as Ethereum, including coins with significant underlying technology such as EOS, XLM, ADA and NEO, and altcoin trading platforms, such as Binance and Bittrex. In addition, this course will provide instruction on how to use information such as a coin’s underlying utility, how to use current industry and sector news in combination with technical analysis in an effort to maximize returns; and how to effectively scrutinize and understand social media feeds.

Bitcoin Trading 301: Professional ICO analyst, Preston Hom, will teach students what to look for when vetting a new cryptocurrency offering, including how to read a white paper, how to analyze the professional teams and advisory boards associated with an offering, the role that technology, marketing, trends play and what pitfalls to avoid.

“We are excited to expand our cryptocurrency education platform with the launch of Bitcoin Trading Academy, a cutting-edge cryptocurrency trading education center which follows the Company’s successful November 2017 launch of newcoins168.com, a Chinese language cryptocurrency and blockchain technology news and information site. In addition to online courses, Bitcoin Trading Academy will offer live courses in New York City,” says ChineseInvestors.com, Inc. CEO Warren Wang.

Online courses will begin June 9, 2018.  Additional course information will be provided on http://www.newcoins168.com .

About ChineseInvestors.com (OTCQB: CIIX)

Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail, online sales and direct sales of hemp-based products and other health related products.

For more information visit: ChineseInvestors.com

Visit and register https://www.newcoins168.com

Subscribe and watch our video commentaries: https://www.youtube.com/user/Chinesefncom

Subscribe and watch our video commentaries: https://www.youtube.com/channel/UCriTFjFHCvDW_LBhiIeuLlQ/featured

Follow us on Twitter for real-time Company updates: https://twitter.com/ChineseFNEnglsh

Like us on Facebook to receive live feeds: https://www.facebook.com/Chinesefncom

https://www.facebook.com/Chineseinvestors.com.english

Add us on WeChat: Chinesefn or download iPhone iOS App: Chinesefn.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

 

Contact:
ChineseInvestors.com, Inc.
227 W. Valley Blvd, #208 A
San Gabriel, CA 91776

Investor Relations:
Alan Klitenic
+1-214-636-2548

Corporate Communications:
NetworkNewsWire (NNW)
New York, New York
http://www.NetworkNewsWire.com
+212-418-1217 Office
Editor@NetworkNewsWire.com

Monday, April 30th, 2018 Uncategorized Comments Off on $CIIX Cryptocurrency Trading Courses via Bitcoin Trading Academy, Starting June 9

$ETST Plans to Battle Opioid Addiction with Human Clinical Trials in 2019

  • Centers for Disease Control and Prevention, in March 2018, estimated ‘economic burden’ of opioid misuse at $78.5 billion annually
  • ETST plans to complete white paper, begin human clinical trials by 2019; company intends to investigate drugs that combine mineral element and cannabinoid industrial hemp oil
  • Goal for biotech company is to fight opioid addiction with over-the-counter (OTC) treatment drug and a cannabinoid companion generic drug

Earth Science Tech, Inc. (OTC: ETST) is planning to fight opioid addiction in the near future by completing its white paper and beginning human clinical trials in 2019. The epidemic is projected to claim nearly 500,000 American lives by 2027, according to a study by STAT (http://nnw.fm/9Twid).

The ETST white paper and planned human clinical studies deal with the measure of the efficacy of combination drugs against opioid dependency. The company will investigate the synergies between mineral elements and full spectrum cannabinoid industrial hemp with the goal of developing OTC and generic drugs that treat opioid addiction.

ETST is a biotech company focused on the cannabinoid, pharmaceutical and nutraceutical markets. In addition to drug research, it also performs R&D testing for medical devices. The company holds several subsidiaries, including Earth Science Pharmaceutical, Inc.; Cannabis Therapeutics, Inc.; KannaBidioiD, Inc.; and Canna Inno Laboratories, Inc., based in Montreal, Canada.

The company’s proposed OTC drug would be intended to reduce the cravings of opioid addicts. The other would be a generic designed to reduce the danger of side effects and make the first drug more effective, according to ETST. The purpose of the human trial is to develop a methodology that prevents fatal overdoses and relieves the side effects of withdrawal.

The Centers for Disease Control and Prevention (CDC), in a March 2018 revised report, estimated the ‘economic burden’ of opioid misuse at $78.5 billion annually in the U.S., including in that figure health care, addiction treatment and the involvement of the justice system. The National Institute on Drug Abuse terms it a national health crisis (http://nnw.fm/se3kA).

For more information, visit the company’s website at www.EarthScienceTech.com

More from NetworkNewsWire

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Friday, April 27th, 2018 Uncategorized Comments Off on $ETST Plans to Battle Opioid Addiction with Human Clinical Trials in 2019

$NETE Sees Rising Organic Growth

  • Revenues increased 11 percent during 2017, reaching $60.1 million on organic growth across all categories
  • Point of sale market expected to reach $106 billion by 2025
  • Global retail e-commerce sales to post solid gains, rising by more than 23 percent to $2.3 trillion by end of 2017 and accounting for 10 percent of total retail sales
  • Net Element processed $2.8 billion in global transactions in 2017, a 14 percent increase
  • Fast Pass Funding service unveiled on proprietary Netevia platform

Net Element, Inc. (NASDAQ: NETE), a global technology and value-added solutions group focused on supporting electronic payments acceptance in a multichannel environment, continues to master the art of the transaction by delivering valuable payment solutions to merchants and consumers.

E-commerce continues to show a healthy growth pattern, as consumers are increasingly dedicated to using their mobile devices to make purchases. According to a report compiled by Accenture Consulting (http://nnw.fm/4jY5q), consumer awareness of mobile payments is at an all-time high and first movers that deliver additional value to merchants and their customers will become the industry’s ‘game changers’.

Net Element’s new service, Fast Pass Funding, provided through the company’s proprietary Netevia platform (http://nnw.fm/jAfq4), is just one of the company’s innovative value-added services offered to merchants who are tired of waiting for funding to be processed. Eligible merchants receive funds in as little as three hours during regular business days, avoiding the 12 to 24 hour wait-time they normally endure. Other value-added services offered through the Netevia platform include fast, easy merchant account opening and integration, payment conversion optimization, over 150 risk-monitoring filters and highly competitive pricing for payment acceptance services.

People around the world are expected to make 726 billion transactions using digital payment technologies by 2020, according to an article published by CNBC (http://nnw.fm/Wa9uq). Based on analysis of payment trends during the years 2014 and 2015, the study – conducted by global consulting firm Capgemini – reported that debit cards accounted for the highest share of non-cash payments at 46.7 percent, while credit cards trailed behind at 19.5 percent. Non-cash transactions between 2014 and 2015 rose 11.2 percent, the highest growth of the past decade.

Net Element intends to capitalize on the mobile transaction market as it transforms to meet demands by consumers and merchants who pivot to embrace smart technology trends. The company’s key goals include continuing company growth in all key segments, driving client retention, expanding the company’s client base in particular markets, delivering value-added products to increase efficiencies and payment acceptance, continuing the development of Netevia and launching new tools to reach clients and deepen partner relations.

“We are very pleased with our 2017 progress and the strong balance sheet position as of December 31, 2017, which we believe positions the company for future growth and opportunities,” Firer said in a news release describing the company’s year in review and plans for 2018 (http://nnw.fm/oJS8A).

For more information, visit the company’s website at www.NetElement.com

More from NetworkNewsWire

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Friday, April 27th, 2018 Uncategorized Comments Off on $NETE Sees Rising Organic Growth

$CIIX Eyes Chinese Expansion with Establishment of Shanghai-Based Subsidiary

  • Announces expansion of cryptocurrency and blockchain education business into China
  • Set to provide 24/7 coverage of the latest developments in global cryptocurrency and blockchain industry
  • Launching Bitcoin Trading Academy to grow subscribers

ChineseInvestors.com, Inc. (OTCQB: CIIX) recently announced its expansion into China through the establishment of NewCoins168.com Digital Media Technology Ltd., located in Shanghai (http://cnw.fm/B6Grt). This wholly owned foreign enterprise is registered in the China Free Trade Zone with capital of 10 million RMB ($1.58 million). This expansion strengthens the company’s vision of becoming the premier financial information website for Chinese-speaking investors. CIIX prides itself on being an innovative company providing real-time market commentary, analysis and educational services in Chinese language character sets (traditional and simplified).

The company plans to hire 10 to 15 editors in Shanghai to work in conjunction with their United States counterparts at www.NewCoins168.com, which was established in November 2017 and is headquartered in New York City’s Trump Building. This joint effort between Shanghai and the United States editors will result in 24/7 coverage of the latest in global cryptocurrency and blockchain industry developments.

CIIX, through the NewCoins168.com platform, has established itself as a well-known cryptocurrency and blockchain technology information portal for the North American Chinese community. The addition of the Shanghai enterprise positions the company to bolster its popularity among the Chinese community worldwide.

CIIX Chief Executive Officer Warren Wang announced the company’s plans to launch a Bitcoin Trading Academy in June. It is expected to broadcast on NewCoins168.com. This academy will feature a three-level bitcoin trading course for Chinese-speaking investors in the U.S. (http://cnw.fm/Pec00). These courses will consist of trading in bitcoin futures, educational research and an explanation of ICOs. The recent announcement to spin off CIIX’s CBD-focused assets into a private company allows CIIX to remain focused on financial consulting, corporate brand building and educational services for cryptocurrency markets. CIIX’s focus has returned to its core skills as a financial service business for the Chinese-speaking community.

For more information, visit the company’s website at www.ChineseInvestors.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Friday, April 27th, 2018 Uncategorized Comments Off on $CIIX Eyes Chinese Expansion with Establishment of Shanghai-Based Subsidiary

$SNNVF Delivers High-quality Products and Services to Cannabis Markets

April 19, 2018

  • Uniquely positioned in the largest legalized medical and recreational cannabis markets – California and Canada
  • Construction underway for a modern, agri-technology greenhouse facility in California capable of producing over 100,000 kg of premium medical cannabis annually, once phase 1 and 2 are complete
  • Received all required California temporary licenses to cultivate, process cannabis; will apply for annual state licenses within next four months
  • Designs completed for purpose-built current Good Manufacturing Practice (cGMP) compliant greenhouse facilities in British Columbia capable of producing 100,000 kg of premium medical cannabis per year and over 25,000 kg of trim used for extraction
  • Application for medical cannabis production license at BC facility from Health Canada under final review

Sunniva Inc. (CSE: SNN) (OTCQX: SNNVF) is a vertically integrated medical cannabis company operating in the world’s two largest cannabis markets – Canada and California – committed to delivering safe, consistent, high-quality products and services. Sunniva operates through its wholly owned subsidiaries: Sunniva Medical Inc., CP Logistics, LLC, Natural Health Service Ltd., and Full-Scale Distributors, LLC. Sunniva’s vision is to become the lowest cost, highest quality cannabis producer in the markets it serves by building large scale purpose-built cGMP compliant greenhouses, offering best quality assurance with cannabis products free from pesticides, providing better patient and doctor access to cannabis education, and sourcing better therapeutic delivery devices.

The company is establishing sophisticated distribution channels, including Sunniva’s ownership of Natural Health Services Ltd. cannabis clinics in Canada with over 95,000 active patients, to purchase the significant quantities of high quality Sunniva-branded and Sunniva private-labeled cannabis products.

Sunniva is an ancient English name which means, “Gift of the Sun.” Sunniva’s team of horticulturists, scientists and engineers is helping to set best practices for the industry, believing that sun-grown, solar-powered cultivation is the most sustainable and cost-effective way to grow high-quality, premium cannabis.

The Sunniva Family includes:

CP Logistics, LLC

Through its subsidiary, CP Logistics LLC, Sunniva is developing the Sunniva Campus, a state-of-the-art, purpose-built greenhouse facility in Cathedral City, California. This modern purpose-built, agri-technology greenhouse is designed to be cGMP compliant which assures proper design, monitoring and control of manufacturing processes and facilities.

Phase 1 of the project includes a fully funded 325,000 square foot greenhouse capable of producing 60,000 kg per year of dry cannabis at capacity with operations commencing Q3 2018. Approximately 50 percent of initial total production will be converted into oils and extracts. Phase 2 is expected to increase the greenhouse by 165,000 square feet and grow production by about 40,000 kgs. per year.

These uniquely sealed greenhouses are designed to deploy custom, automation assembly line cultivation processes at a large scale. Energy consumption will be reduced while utilizing the energy of the sun and microclimatic controls to provide precise growing conditions. The greenhouse will recirculate air for more efficient climate control, and the company’s Integrated Pest Management System is designed to ensure every plant grown is certified clean and free of all contaminants and pesticides.

Sunniva Medical Inc.

Sunniva Medical Inc. is designing and preparing to break ground on the Sunniva Canada Campus encompassing 700,000 square feet of purpose-built cGMP greenhouse facilities in the Okanagan Valley, British Columbia. The total campus is expected to produce 100,000 kg of premium medical cannabis annually plus additional trim used for extraction. This facility will produce pesticide-free products and will convert trim to extracted products such as cannabis oil that can be used for drug delivery formats such as capsules, dissolvable strips, vaporization cartridges, tinctures and creams.

Sunniva and Canopy Growth Corporation (Canopy Growth) recently announced a large take or pay supply agreement. Under the terms of the agreement, Canopy Growth will purchase up to 45,000 kgs. of dried cannabis annually commencing Q1 2019, which includes the distribution of Sunniva branded products. Sunniva Medical is a late-stage applicant under Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR) and is in the final review stage of the process.

Natural Health Services Ltd.

Natural Health Services Ltd. owns and operates a network of eight medical clinics in Canada specializing in medical cannabis under the ACMPR. Natural Health Services connects licensed producers to their 21 physicians and patients with its proprietary SPARK software which utilizes a software-as-a-service revenue model. To date, there are 27 integrated licensed producers utilizing the SPARK software.

In-house physicians specializing in the endocannabinoid system provide expert consultation, education and recommendations for targeted phytoceutical remedies and wellness plans to improve the quality of life for all patients. NHS enjoys a long-term relationship with patients due to the quality of its physician-patient experience. A rapidly expanding NHS cannabis clinic network serves 94,000 active patients in Canada. NHS has also initiated a pilot program with a national pharmacy chain to aggregate more patients.

Full-Scale Distributors, LLC

Full-Scale Distributors, LLC is an industry leading provider of custom, private-label vaporizers through its brand, Vapor Connoisseur. The company currently serves the needs of over 80 top brands in the North American marketplace. Vapor Connoisseur is recognized for its high quality and innovative therapeutic delivery devices. Products are tailored to client needs, ensuring both safety and reliability.

Sunniva’s highly experienced management team is building partnerships with leading scientists, universities and clinical trial groups to deliver proprietary cannabis formulations to a broad spectrum of health ailments and conditions. These global partners require cGMP-certified facilities for the processing and manufacturing of cannabis products. Sunniva is committed to providing safe, pesticide-free, high quality, reproducible cannabis medicines.

Leading Sunniva is co-founder, chairman and CEO Dr. Anthony (Tony) Holler. He is the former CEO and founder of ID Biomedical, which was acquired in 2005 for $1.7 billion by GlaxoSmithKline. He is also the former chairman of Corriente Resources Inc., which was sold for approximately $700 million to CRCC-Tongguan Investment Co. Dr. Holler is currently chairman of CRH Medical Corporation, a public company trading on the TSX and NYSE. His expertise includes strategic planning, mergers and acquisitions and financing with a singular focus on increasing shareholder value.

Dr. Holler is joined by co-founder Leith Pedersen, who serves as president of Sunniva. Pedersen is the former owner and CEO of Vida Wealth Management Bahamas and was a former investment advisor at Canaccord Wealth Management. He is a former partner and director at JF Mackie and Company, an independent brokerage firm in Calgary, Alberta, that managed capital in excess of $2 billion for high net worth clients. Pedersen’s expertise is in corporate strategy, financing and mergers and acquisitions.

For more information, visit the company’s website at www.sunniva.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Friday, April 27th, 2018 Uncategorized Comments Off on $SNNVF Delivers High-quality Products and Services to Cannabis Markets

$AXSM Positive Outcome of Interim Analysis of STRIDE-1 in Depression

Independent Data Monitoring Committee recommends trial continuation

Second interim analysis anticipated second half of 2018 for efficacy

NEW YORK, April 26, 2018 — Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced a positive outcome of the interim futility analysis for the STRIDE-1 Phase 3 trial of AXS-05 in treatment resistant depression. An independent data monitoring committee (IDMC) conducted the unblinded, pre-specified interim analysis. Based on the results of the analysis, the IDMC recommended that the trial continue. The IDMC also reviewed the available safety information from the study and indicated that, based on the interim results, AXS-05 appeared safe and well-tolerated.

AXS-05 is a novel, oral, fixed-dose combination of dextromethorphan and bupropion. AXS-05 combines glutamatergic and monoaminergic mechanisms of action, which have been associated with antidepressant effects, and Axsome’s metabolic inhibition technology. Pharmacokinetic data with AXS-05 and clinical observations with the dextromethorphan component indicate that AXS-05 increases dextromethorphan concentrations into a potentially therapeutic range. AXS-05 has been granted U.S. Food and Drug Administration (FDA) Fast Track designation for the treatment of treatment resistant depression.

“The positive outcome of this interim futility analysis combined with the multiple mechanisms of action of AXS-05 support its continued development for treatment resistant depression,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. “We look forward to the next and final interim analysis of the STRIDE-1 trial, anticipated in the second half of this year, which will be conducted to assess efficacy.”

The STRIDE-1 interim futility analysis was performed on the first approximately 40% of the target number of subjects. A second interim analysis will be performed on the first approximately 60% of the target number of subjects to assess efficacy.

“The IDMC’s recommendation for continuation of the STRIDE-1 trial and its findings of an overall favorable clinical safety profile for AXS-05 are encouraging,” said Cedric O’Gorman, MD, Senior Vice President of Clinical Development and Medical Affairs of Axsome. “A significant proportion of patients with major depressive disorder are treatment resistant, having previously failed two or more therapies. There are limited available treatment options for these patients. AXS-05’s multiple mechanisms, targeting glutamatergic, monoaminergic and anti-inflammatory pathways, may offer a unique therapeutic approach for this serious condition.”

The Company recently held a research and development (R&D) day focusing on AXS-05. Of relevance to treatment resistant depression were presentations by key opinion leaders Stephen M. Stahl, MD, PhD, DSc (Adjunct Professor of Psychiatry, University of California San Diego), and Maurizio Fava, MD (Executive Vice Chair of the Department of Psychiatry, Massachusetts General Hospital). Dr. Stahl discussed the psychopharmacology of AXS-05 and its potential clinical implications. Dr. Fava discussed approaches that target multiple mechanisms of action to address treatment resistant depression, and the potential utility of AXS-05 for this condition. An archived webcast of this event, with slides, can be accessed on the investor page of Axsome’s website at www.axsome.com.

The R&D day also featured presentations from key opinion leaders Marc Agronin, MD (Vice President of Behavioral Health and Clinical Research at Miami Jewish Health), who discussed the potential of AXS-05 for the treatment of agitation associated with Alzheimer’s disease, and James Davis, MD (Medical Director of the Duke Center for Smoking Cessation, Duke University School of Medicine), who discussed unmet needs in smoking cessation and the potential for AXS-05.

About the STRIDE-1 Study

STRIDE-1 (Symptom Treatment in Resistant Depression 1) is a Phase 3, randomized, double-blind, active controlled trial to assess the efficacy and safety of AXS-05 in the treatment of treatment resistant depression (TRD). Patients with major depressive disorder (MDD) who have previously failed one or two antidepressant treatments are treated in an open-label fashion with bupropion during a 6-week lead-in period. Patients who fail to respond to bupropion during this lead-in period are randomly assigned in a 1:1 ratio to receive bupropion or AXS-05 in a double-blind fashion for 6 weeks. The primary endpoint is the change in the Montgomery-Åsberg Depression Rating Scale (MADRS) after 6 weeks of treatment.

About Treatment Resistant Depression (TRD)

Patients diagnosed with major depressive disorder (MDD) are defined as having TRD if they have failed two or more antidepressant therapies. MDD is a serious condition characterized by depressed mood or a loss of interest or pleasure in daily activities consistently for at least a two-week period, and which impairs social, occupational, educational, or other important functioning. According to the National Institute of Health, an estimated 6.7% of U.S. adults experience MDD each year. Nearly two-thirds of diagnosed and treated patients do not experience adequate treatment response with first-line therapy, and the majority of these initial failures also fail second-line treatment.

About AXS-05

AXS-05 is a novel, oral, investigational drug product under development for the treatment of central nervous system (CNS) disorders. AXS-05 consists of bupropion and dextromethorphan and utilizes Axsome’s metabolic inhibition technology. Dextromethorphan is an NMDA receptor antagonist, sigma-1 receptor agonist, nicotinic acetylcholine receptor antagonist, and inhibitor of the serotonin and norepinephrine transporters. Bupropion serves to increase the bioavailability of dextromethorphan, and is a norepinephrine and dopamine reuptake inhibitor, and a nicotinic acetylcholine receptor antagonist. AXS-05 is an investigational drug product not approved by the FDA. The safety and efficacy of AXS-05 have not yet been established.

About Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. Axsome’s product candidate portfolio includes five clinical-stage candidates, AXS-02, AXS-05, AXS-06, AXS-07, and AXS-09. AXS-05 is currently in a Phase 3 trial in treatment resistant depression (TRD), a Phase 2/3 trial in agitation associated with Alzheimer’s disease (AD), and a Phase 2 trial in smoking cessation. AXS-02 is currently in a Phase 3 trial in knee osteoarthritis (OA) associated with bone marrow lesions (BMLs) with an additional Phase 3 trial planned in chronic low back pain (CLBP) associated with Modic changes (MCs). AXS-07 is being developed for the acute treatment of migraine. AXS-06 is being developed for the treatment of osteoarthritis and rheumatoid arthritis and for the reduction of the risk of NSAID-associated gastric ulcers. AXS-02, AXS-05, AXS-06, AXS-07, and AXS-09 are investigational drug products not approved by the FDA. For more information, please visit the company website at www.axsome.com. The company may occasionally disseminate material, nonpublic information on the company website.

Forward Looking Statements

Certain matters discussed in this press release are “forward-looking statements”. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the success, timing and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation and completion of the trials, futility analyses and receipt of interim results, which are not necessarily indicative of the final results of our ongoing clinical trials; our ability to fund additional clinical trials to continue the advancement of our product candidates; the timing of and our ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, our product candidates; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s product candidates, if approved; and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance.

Axsome Contact:
Mark Jacobson
Senior Vice President, Operations
Axsome Therapeutics, Inc.
25 Broadway, 9th Floor
New York, NY 10004
Tel: 212-332-3243
Email: mjacobson@axsome.com
www.axsome.com

Thursday, April 26th, 2018 Uncategorized Comments Off on $AXSM Positive Outcome of Interim Analysis of STRIDE-1 in Depression

$MATR To Be Acquired By NICE

CHICAGO, April 26, 2018 — Mattersight Corporation (NASDAQ:MATR), the pioneer in personality-based software applications, today announced that it has entered into a definitive agreement to be acquired by an affiliate of NICE Ltd., the worldwide leading provider of both cloud and on-premises enterprise software solutions that empower organizations to make smarter decisions based on advanced analytics of structured and unstructured data. Under the terms of the agreement, NICE will launch a tender offer to purchase all outstanding shares of Mattersight’s common and preferred stock, pursuant to which holders of Mattersight’s common stock will receive $2.70 per common share in cash and holders of Mattersight’s outstanding preferred stock will receive $7.80 per share in cash, plus accrued and unpaid dividends as of immediately prior to the closing. The per share purchase price of Mattersight’s common stock represents a 26% premium to the per share closing price of Mattersight’s common stock on the Nasdaq Global Market on April 25, 2018, the last trading day prior to the announcement of the transaction, and a 27% premium to the 30-day weighted-average price per share of Mattersight’s common stock.

“Our solutions drive significant business value for some of the most recognized brands on the planet, but we’ve lacked the resources to rapidly accelerate our growth. This transaction creates a great opportunity for Mattersight’s customers and employees, as NICE brings complementary products, a substantial distribution engine and a strong brand that allow us to accelerate our go-to-market strategy” said Kelly Conway, CEO of Mattersight. “We are excited to work with NICE to bring our personality-based applications to the global market and continue innovating with our current and future customers.”

Mattersight expects the integration of NICE analytics powered by Nexidia and Mattersight’s behavioral analytics technology and domain expertise will allow organizations to enjoy the market’s most advanced analytics in the cloud, driving personalization and smart connections in real time.

“Analytics is the cornerstone of NICE’s strategy of creating a new customer service paradigm with CXone and Adaptive WFO,” said Barak Eilam, CEO of NICE. “We were very impressed with Mattersight’s innovative technology and domain expertise, as well as by their long standing strategic relationships with some of the largest customer service organizations. This acquisition reaffirms our commitment to delivering analytics in the cloud and to be at the forefront of the analytics market.”

The Board of Directors of Mattersight has approved the transaction. The transaction is expected to close in the second half of 2018, subject to completion of the tender offer, as well certain regulatory approvals and other customary closing conditions. The transaction will be funded from NICE’s cash on hand.

Union Square Advisors is serving as the exclusive financial advisor, and Cooley is serving as the legal advisor, to Mattersight.

About Mattersight
Mattersight unleashes the power of personality to improve every interaction with every customer every time. With tools to learn, analyze, and predict customer behavior based on customer conversations, Mattersight helps brands create chemistry with their customers through shorter, more satisfying conversations that increase loyalty. To learn how Mattersight can help you click better with your customers visit www.mattersight.com.

Important Additional Information and Where to Find It

In connection with the proposed acquisition of Mattersight by NICE, NICE will commence a tender offer for all of the outstanding shares of Mattersight’s common stock and preferred stock. Such tender offer has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares of Mattersight, nor is it a substitute for the tender offer materials that NICE will file with the U.S. Securities and Exchange Commission (the “SEC”) upon commencement of the tender offer. At the time that the tender offer is commenced, NICE will file tender offer materials on Schedule TO with the SEC, and Mattersight will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the offer. THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION THAT SHOULD BE READ CAREFULLY AND CONSIDERED BY MATTERSIGHT’S STOCKHOLDERS BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. Both the tender offer statement and the solicitation/recommendation statement will be made available to Mattersight’s stockholders free of charge. A free copy of the tender offer statement and the solicitation/recommendation statement will also be made available to all stockholders of Mattersight by contacting Mattersight at Legal Department, Mattersight Corporation, 200 W. Madison Street, Suite 3100, Chicago, Illinois 60606, by phone at 877.235.6925, or by visiting Mattersight’s website (www.mattersight.com). In addition, the tender offer statement and the solicitation/recommendation statement (and all other documents filed with the SEC) will be available at no charge on the SEC’s website (www.sec.gov) upon filing with the SEC. MATTERSIGHT’S STOCKHOLDERS ARE ADVISED TO READ THE TENDER OFFER STATEMENT AND THE SOLICITATION/RECOMMENDATION STATEMENT, AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BEFORE THEY MAKE ANY DECISION WITH RESPECT TO THE TENDER OFFER BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES TO THE TRANSACTION.

Forward-Looking Statements

This document contains certain statements that constitute forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the satisfaction of conditions to the completion of the proposed transaction and the expected completion of the proposed transaction, as well as other statements that are not historical fact. These forward-looking statements are based on currently available information, as well as Mattersight’s views and assumptions regarding future events as of the time such statements are being made. Such forward looking statements are subject to inherent risks and uncertainties. Accordingly, actual results may differ materially and adversely from those expressed or implied in such forward-looking statements. Such risks and uncertainties include, but are not limited to, the potential failure to satisfy conditions to the completion of the proposed transaction due to the failure to receive a sufficient number of tendered shares in the tender offer, as well as those described in cautionary statements contained elsewhere herein and in Mattersight’s periodic reports filed with the SEC including the statements set forth under “Risk Factors” set forth in Mattersight’s most recent annual report on Form 10-K, the Tender Offer Statement on Schedule TO (including the offer to purchase, the letter of transmittal and other documents relating to the tender offer) to be filed by NICE, and the Solicitation/Recommendation Statement on Schedule 14D-9 to be filed by Mattersight. As a result of these and other risks, the proposed transaction may not be completed on the timeframe expected or at all. These forward-looking statements reflect Mattersight’s expectations as of the date of this report. While Mattersight may elect to update any such forward-looking statements at some point in the future, Mattersight specifically disclaims any obligation to do so, even if our expectations change, except as required by law.

Contact
David Mullen
Chief Financial Officer
312.954.7380
dave.mullen@mattersight.com

Thursday, April 26th, 2018 Uncategorized Comments Off on $MATR To Be Acquired By NICE

$NETE is Enabling Business across a Wide Array of Platforms

April 26, 2018

  • Retail e-commerce sales expected to reach $4.88 trillion by 2021
  • Net Element enables expanding scope of face-to-face and e-commerce transactions
  • Company building additional transaction capabilities through blockchain project

In a world with rapidly expanding opportunities for commerce at a truly worldwide scale, one of the greatest challenges businesses face is staying abreast of the technologies that keep people linked together across the globe. Net Element, Inc. (NASDAQ: NETE) is in the business of making business happen, ensuring that sales transactions can take place across a wide array of potential platforms, globally or in-person right at a merchant’s store.

Not so far from the historical era of bartering for goods and services and yet light years ahead in terms of mobility, modern businesses and consumers are increasingly accustomed to moving merchandise without a ‘show-me-the-money’ mentality. Payment cards, emailed and texted statements and short-range electronic broadcasting all serve to verify in a confident and practically instantaneous manner that a resource of funds sufficient to cover a debt exists somewhere in the world and can be made available to another specified location somewhere in the world.

Through its brands, Net Element specializes in linking consumer mobile phones, banks, unbanked online distribution outlets and offline brick-and-mortar storefronts, providing value-added services and business analytics.  The goal is to help companies assess their competition, evaluate their own productivity and get to know their clients’ preferences in the U.S. and emerging markets around the globe.

The company’s North America Transactions Solutions business segment recorded year-over-year revenue growth of 21 percent in 2017 with a history of 28 percent growth, driven mostly by its successes with its Unified Payments subsidiary (http://nnw.fm/zV1H8). Unified Payments’ Fast Pass Funding service gives eligible merchants access to revenues in as little as three hours during regular business days, improving turnaround time for transaction processing to same-day significance.

Entry into the Enterprise Ethereum Alliance has bolstered the company’s development of secure blockchain protocols to enhance its transaction solutions, including its new Netevia multi-channel payments platform that offers end-to-end processing through easy-to-use APIs. The company’s other subsidiaries — international small content mobile solution entity Digital Provider, cloud-based point-of-sale wireless tech platform Aptito, and processor agnostic e-commerce manager PayOnline — enhance its gravitas in the industry.

Independent equity research firm JGR Capital announced in April that it had launched its small cap data coverage of Net Element as a service to investors and shareholders (http://nnw.fm/M2ieN), providing additional attention to the company’s capabilities. In January, Net Element wrapped up a $7.55 million restricted common stock and warrant private placement with an institutional investor than brought in additional funding for its blockchain initiatives.

“The Company’s balance sheet is now the strongest in its history, allowing Net Element to support future growth opportunities,” Net Element CEO Oleg Firer stated in a news release.

Cumulative data from market analyst Statista projects that retail e-commerce sales worldwide will continue to grow at a marked pace, doubling revenues to $4.88 trillion by 2021. The analysis reports that online shopping is one of the most popular online activities worldwide, but the usage varies by region. In 2016, an estimated 19 percent of all retail sales in China occurred via internet, but, in Japan, the share was only 6.7 percent. Desktop PCs are still the most popular device for placing online shopping orders, but mobile devices, especially smartphones, are catching up, the report states (http://nnw.fm/sy5E3).

For more information, visit the company’s website at www.NetElement.com

More from NetworkNewsWire

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Thursday, April 26th, 2018 Uncategorized Comments Off on $NETE is Enabling Business across a Wide Array of Platforms

$DJACF Marijuana Stocks Close Mixed As Sessions Supports Cannabis Research

The North American Marijuana Index fell flat on Wednesday, as pot stocks closed mixed following news of U.S. Attorney General Jeff Sessions’ openness to medical marijuana research. Sessions, known for his opposition to cannabis, told a key Senate panel on Wednesday that not only does he believe medical marijuana may have benefits, but that it should be researched as well. Still, the head of the Justice Department continues to doubt findings that cannabis may aid in dealing with the opioid epidemic, stating he doesn’t “believe that will be sustained in the long run.” The Index fell 1.70 points, or 0.69 percent, to close out the day at 245.86.

The United States Marijuana Index rose 0.42 points, an increase of 0.48 percent to close out the day at 88.51, while the Canadian Marijuana Index fell 9.98 points, or 1.58 percent, ending the day at 621.33.

Wall Street pulled out a mixed win on Wednesday despite investor worries over U.S. bond yields that continue to rise as well as growing corporate costs. Adding to the positive numbers, around 31 percent of the S&P 500 companies have reported earnings so far, with the bulk of those meeting or beating consensus estimates. Thomson Reuters data shows that analysts expect growth of 22 percent for the first quarter.

Still, some experts remain trepidatious about the market’s future. “Investors are aware that the tax cuts have certainly boosted earnings and they have also seen an increase in top line growth,” said Bernard Baumohl, chief global economist at the Economic Outlook Group in an interview with Reuters.

“But we are a bit long in the tooth with respect to this cycle. Interest rates are also moving higher. And at some point there is a question how much longer this economic expansion can continue to grow.”

In a CJS Approps Subcmte hearing I raised the conflicts between state & federal marijuana law, asking AG Jeff Sessions for assurances that the Department of Justice will act as an ally, rather than an obstacle, in considering future legislation respecting states’ rights. pic.twitter.com/UvFiTaW2Sg

— Sen. Lisa Murkowski (@lisamurkowski) April 25, 2018

The Dow Jones Industrial Average gained 59.7 points, or 0.25 percent, to end the day at 24,083.83, while the S&P 500 rose 4.84 points, an increase of 0.18 percent, to close out Wednesday at 2,639.4. Finally, the Nasdaq Composite fell 3.62 points, or 0.05 percent, to end the day at 7,003.74.

The Horizons Marijuana Life Sciences ETF (HMMJ.TO) fell CAD$0.26 per share, a loss of 1.59 percent to close out the day at CAD$16.14 per share, while the Evolve Marijuana ETF (SEED.TO) fell CAD$0.28 per share, or 1.65 percent, to end the day at CAD$16.66 per share.

Hiku Brands and WeedMD Merge

They might not be the ‘27 Yankees, but last week’s announcement from Hiku Brands Company Ltd. (CSE:HIKU) and WeedMD Inc. (TSX-V:WMD) (OTC:WDDMF) that the two companies had agreed to merge brings together a couple of cannabis powerhouses. According to a statement, shareholders of  Hiku and WeedMD will own approximately 51.75 percent and 48.25 percent of the new entity, respectively, which will be listed on the TSX-Venture. The deal gives the newly formed company four indoor and greenhouse growing facilities with a capacity that will exceed 56,000 kg by the middle of 2019.

“Our vision at Hiku has always been that cannabis is a consumer product – in which brands, retail and customer experience will ultimately win,” said Alan Gertner, Chief Executive Officer of Hiku in a statement. “The combination of Hiku and WeedMD creates a cannabis company capable of fulfilling the vision of delivering the best in class experiences from in-store to product, from medical to adult-use, but also capturing full retail and wholesale margins. Our combined offerings create a company that is insulated from potential wholesale margin compression and is ready to scale its offering globally.”

Quick Hits

Naturally Splendid Enterprises Ltd. (TSX-V:NSP) (OTCQB:NSPDF) acquired organic hemp processor Absorbent Concepts Inc…  Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) announced new clinical trial data… Kaya Holdings, Inc. (OTCQB:KAYS) opened its fourth marijuana dispensary in Oregon.

Thursday, April 26th, 2018 Uncategorized Comments Off on $DJACF Marijuana Stocks Close Mixed As Sessions Supports Cannabis Research

$SNNVF Earnings Release Update Covered by NetworkNewsAudio

NEW YORK, April 26, 2018 — via NetworkWire – NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company for business, today announces the audio version of Sunniva Inc. (CSE:SNN) (OTCQX:SNNVF) recent press release titled “Sunniva Inc. to Delay Earnings Release Until April 30, 2018.”

To hear the Sunniva Inc. AudioPressRelease (APR) version, visit: http://nnw.fm/p6fEC

To read the original press release, visit: http://nnw.fm/Ie6Eq

About Sunniva Inc.

Sunniva, through its subsidiaries, is a vertically integrated medical cannabis company operating in the world’s two largest cannabis markets – Canada and California – where we are committed to delivering safe, high-quality products and services at scale. Our vision is to become the lowest cost, highest quality cannabis producer in the markets we serve by building large scale purpose-built current good manufacturing practices greenhouses, offering better quality assurance with cannabis products free from pesticides, providing better patient and doctor access to cannabis education and sourcing better therapeutic delivery devices. Sunniva’s management and board of directors have a proven track record for creating significant shareholder value both in the healthcare and biotech industries.

For more information please visit: www.sunniva.com

About NetworkNewsAudio

NetworkNewsAudio (NNA) , a NetworkNewsWire (NNW) Solution, allows you to sit back and listen to market updates, CEO interviews and a Company AudioPressRelease (APR). These audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio (NNA) is another NetworkNewsWire (NNW) Solution that can assist your company by cutting through the overload of information in today’s market, NNA brings its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire (NNW) is where news, content and information converge. NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public with an ever-growing distribution network of more than 5,000 key syndication outlets across the nation.

For more information, visit: www.NetworkNewsAudio.com

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets, (3) enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, please visit NetworkNewsWire (NNW).

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications Contact: 

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Thursday, April 26th, 2018 Uncategorized Comments Off on $SNNVF Earnings Release Update Covered by NetworkNewsAudio

$HMMR NetworkNewsWire Coverage Initiated

NEW YORK, April 26, 2018 — via NetworkNewsWire – Hammer Fiber Optic Holdings Corp. (OTCQB:HMMR), a telecommunications company investing in the future of wireless technology, announces it has engaged the corporate communications expertise of NetworkNewsWire (“NNW”).

Hammer Fiber Optic Holdings Corp. (OTCQB:HMMR), with headquarters in New Jersey, serves residential and small business markets with high-capacity broadband, voice and video through direct fiber as well as its wireless fiber platform – Hammer Wireless® AIR technology. The company’s holdings include Hammer Fiber Optic Investments Ltd., D/B/A Hammer Communications, an Internet Service Provider (ISP) that offers internet, voice, video and data services in New Jersey as well as carrier services in Philadelphia and New York.

NNW is a multifaceted financial news and publishing company that delivers a new generation of social communication solutions, news aggregation and syndication, and enhanced news release services. NNW’s strategies help public and private organizations find their voice and build market visibility. As part of the Client-Partner relationship with Hammer Fiber Optic Holdings Corp., NNW will leverage its investor-based distribution network of over 5,000 key syndication outlets, various newsletters, social media channels, blogs, and other outreach tools to generate greater brand awareness for the Company.

“Hammer Fiber’s leadership team has a successful track record in a variety of related industries, as well as a deep knowledge of the regional competitive telecommunications landscape,” states Sherri Franklin, Director of Brand Awareness Distribution (BAD) Solutions for NNW. “We look forward to working with these professionals to launch a corporate communications campaign that keeps the investment community up-to-date on Hammer Fiber’s operations and technology.”

About Hammer Communications

Hammer Fiber Optic Holdings Corp. (OTCQB:HMMR) is a telecommunications company investing in the future of wireless technology whose holdings include Hammer Fiber Optic Investments, Ltd. D/B/A Hammer Communications, a New Jersey-based Internet Service Provider (ISP) that offers internet, voice, video and data services in New Jersey, as well as carrier services in Philadelphia and New York. Hammer Fiber serves residential and small business markets with high capacity broadband, voice and video through both direct fiber as well as its wireless fiber platform, Hammer Wireless® AIR technology.

For more information, visit the company’s website at www.HammerComm.com.

Frank J. Pena
Director of Investor Relations
Hammer Fiber
Phone: 732-333-3808
E-mail: fpena@hammerfiber.com

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets, (3) enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com.

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications Contact:

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Thursday, April 26th, 2018 Uncategorized Comments Off on $HMMR NetworkNewsWire Coverage Initiated

$HMMR Why Hammer Fiber Optic Holdings Corp. is “One to Watch”

April 19, 2018

  • Expansion of IAAS cloud services to support cryptocurrency mining entities in deployment of blockchain technologies
  • Serving residential and SME customers over high-capacity wireless broadband technology using licensed LMDS spectrum
  • Global fiber optics market projected to grow from $3.2 billion in 2017 to $5 billion in 2022 with a CAGR of 9.4%

Hammer Fiber Optic Holdings Corp. (OTCQB: HMMR), with headquarters in New Jersey, is a telecommunications company investing in the future of wireless technology. The company’s holdings include Hammer Fiber Optic Investments, Ltd., D/B/A Hammer Fiber, an Internet Service Provider (ISP) that offers internet, voice, video and data services in New Jersey as well as carrier services in Philadelphia and New York. Hammer Fiber serves residential and small business markets with high-capacity broadband, voice and video through direct fiber as well as its wireless fiber platform – Hammer Wireless® AIR technology.

Hammer Fiber recently completed the initial development phase of its advanced LTE fixed wireless system, which was designed and built upon its successfully deployed wireless technology suite. The expansion allows Hammer Fiber to add ultra-high capacity cellular broadband applications to its product portfolio including wholesale services such as backhaul support for cellular network operators. Designed to complement Hammer Fiber’s core business of home residential service, the company expects this latest innovation to help position Hammer Fiber as a leader in future 5G technology. The company intends to leverage the Fixed LTE system in conjunction with its already deployed Fixed Wireless DOCSIS 3.1 system to deliver on one of its core promises, to deliver high capacity broadband to markets across the country at dramatically lower cost than traditional wireline methods, including fiber. Live field testing of the new system begins in early 2018 in the U.S. with service availability to follow later in the year.

Hammer Fiber has also expanded its IaaS (Infrastructure-as-a-Service) cloud services to include support for the cryptocurrency and blockchain industry. Interested companies will be able to host their products over Hammer Fiber’s robust and modern server infrastructure, fiber network architecture and data center presence in some of the most secure locations in the New York, New Jersey and Philadelphia regions. Hammer Fiber’s servers feature best-in-class computing power, designed to allow enterprise businesses to reap the benefits of utilizing a cloud-based system without the massive cost of establishing or maintaining a corporate data center.

“Distributed architecture infrastructure, such as those utilized by blockchain entities mining cryptocurrencies or other new vertical markets utilizing blockchain technology, are growing exponentially and we are poised to fulfill a critical but fundamental need of this explosive new industry,” said Mark Stogdill, CEO of Hammer Fiber. “The distributed ledger architectures that blockchains are built on require secure and robust data processing networks, highly scalable power generation and a reliable fiber optic backbone infrastructure linking up data centers worldwide for them to exist, and that is what we at Hammer Fiber do really well.”

Hammer Fiber seeks to achieve its vision by employing an extremely qualified group of business professionals with diverse backgrounds and successful track records from a variety of related industries. HMMR’s seasoned leadership team combines startup expertise with a consummate understanding of the regional competitive telecommunications landscape in sales, marketing, engineering, construction and business development.

For more information, visit the company’s website at www.HammerCorp.info

More from NetworkNewsWire

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Wednesday, April 25th, 2018 Uncategorized Comments Off on $HMMR Why Hammer Fiber Optic Holdings Corp. is “One to Watch”

$SNNVF to Delay Earnings Release Until April 30, 2018

VANCOUVER, British Columbia, April 24, 2018 — via NetworkWire – Sunniva Inc. (“Sunniva” or the “Company“) (CSE:SNN) (OTCQX:SNNVF) announced today that it will delay its fourth quarter and year ended December 31, 2017 earnings release and the subsequent earnings call, previously scheduled for April 24, 2018 and April 25, 2018, respectively. The Company now intends to release its results on April 30, 2018, after markets close. The delay is required for the Company’s auditors to complete their final audit procedures.

The Company’s executive management will discuss the results during the rescheduled conference call on Tuesday, May 1, 2018 at 11:30 am Eastern Time/8:30 am Pacific Time. To participate in the call, please dial 1-800-319-4610, or (604) 638-5340. An audio replay will be available shortly after the call by dialing 1-855-669-9658 or (604) 674- 8052 and entering access code 5312. The replay will be available for two weeks after the call.

About Sunniva Inc.

Sunniva, through its subsidiaries, is a vertically integrated medical cannabis company operating in the world’s two largest cannabis markets – Canada and California – where we are committed to delivering safe, high-quality products and services at scale. Our vision is to become the lowest cost, highest quality cannabis producer in the markets we serve by building large scale purpose-built current good manufacturing practices greenhouses, offering better quality assurance with cannabis products free from pesticides, providing better patient and doctor access to cannabis education and sourcing better therapeutic delivery devices. Sunniva’s management and board of directors have a proven track record for creating significant shareholder value both in the healthcare and biotech industries.

For more information please visit: www.sunniva.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information:

Dr. Anthony Holler

Chairman and Chief Executive Officer

Investor Relations Contact:

George Jurcic

Manager, Investor Relations

587-430-0680

ir@sunniva.com

Wednesday, April 25th, 2018 Uncategorized Comments Off on $SNNVF to Delay Earnings Release Until April 30, 2018

$ATOS Endoxifen, Positive Interim Review from Independent Safety Committee

SEATTLE, April 24, 2018 — Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has received a positive interim review on its Phase 1 study of topical endoxifen in men, which is being developed to address gynecomastia (or male breast enlargement), which is a common condition in patients being treated for prostate cancer. The Independent Safety Committee reviewed the blinded data generated from the first group in the study (eight subjects) and concluded that the study may advance to the next dosing level.

“This positive safety determination is on the critical path for a successful outcome of this Phase 1 study in men,” stated Dr. Steven Quay, Ph.D., MD, President and CEO of Atossa. “It is the first assessment of our clinical safety and tolerability data and it indicates that proceeding to the next dosing level with our proprietary topical endoxifen is warranted. We can now advance to the next level of the study which is to escalate the dosage in a new cohort of subjects as we continue to monitor safety and tolerability in the first cohort of the study.” Dr. Quay added, “We believe this is the first clinical trial ever conducted of a topical pharmaceutical for the treatment of gynecomastia. There are no approved drugs, either topical or oral, for this important, unmet medical need which affects 25% of men ages 50-69.”

The objectives of this double-blinded, placebo-controlled, repeat dose study of 24 healthy male subjects is to assess the pharmacokinetics of proprietary formulations of topical endoxifen dosage forms over 28 days, as well as to assess safety and tolerability. The study is being conducted on behalf of Atossa by CPR Pharma Services Pty Ltd., Thebarton, SA, Australia.

About Gynecomastia

Gynecomastia is male breast enlargement and accompanying pain. It is the most common male breast disorder and is caused by a hormone imbalance where testosterone is low compared to estrogen. In prostate cancer treatment, testosterone is suppressed resulting is higher estrogen levels that usually triggers gynecomastia. Prophylactic breast bud irradiation is commonly used in prostate cancer patients, but must often be repeated. One recent study indicates that up to 90% of men taking androgen deprivation therapy suffer from gynecomastia and breast pain (Handoo Rhee, et al., October 18, 2014, BJU International).

According to the Mayo Clinic, although it can affect men at almost any age, it is most prevalent in men ages 50-69, affecting at least 1 in 4 men in this age group. Gynecomastia is caused by, among other things, any number of commonly prescribed medications, such as androgen deprivation therapy to treat prostate enlargement and prostate cancer; anti-anxiety medications; cancer treatments (chemotherapy), and some heart medications. Gynecomastia is not only painful and embarrassing, it can also cause men to stop taking these important medications.

There are no FDA-approved therapeutics for gynecomastia. Breast-bud irradiation, use of compression garments and plastic surgery are the most common approaches used to treat gynecomastia.

About Atossa Genetics

Atossa Genetics Inc. is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit www.atossagenetics.com.

Forward-Looking Statements

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with any variation between preliminary and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa’s products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others with respect to fulvestrant, such as patent rights, potential market sizes for Atossa’s drugs under development and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Atossa Genetics Company Contact:

Atossa Genetics Inc.
Kyle Guse
CFO and General Counsel
(O) 866 893-4927
kyle.guse@atossagenetics.com

Investor Relations Contact:

Scott Gordon
CoreIR
377 Oak Street
Concourse 2
Garden City, NY 11530
Office: 516 222-2560
scottg@CoreIR.com

Tuesday, April 24th, 2018 Uncategorized Comments Off on $ATOS Endoxifen, Positive Interim Review from Independent Safety Committee

$DJACF Early Regulations are Shaping the Future of Canadian Cannabis

NetworkNewsWire Editorial Coverage: North American cannabis markets have achieved tremendous growth in recent years, and that trend shows no sign of slowing down. Cannabis research firm ArcView has called for an annualized growth rate of 26 percent through 2021, as the burgeoning industry benefits from growing popular support and regulatory changes. Perhaps the most notable of these pending amendments is Canada’s planned nationwide legalization of recreational cannabis. Canadian Health Minister Ginette Peitipas Taylor has stoked optimism regarding an August or September 2018 official launch date for recreational cannabis across Canada. Choom Holdings, Inc. (OTCQB: CHOOF) (CSE: CHOO) (CHOOF Profile), with its growing portfolio of four late-stage licensed producer applicants, is primed to pounce on this new market opportunity. Through an aggressive acquisition strategy and strong commitment to developing national retail distribution, Choom has quickly positioned itself as a major player among other North American cannabis industry mainstays like Cronos Group, Inc. (TSX: CRON) (NASDAQ: CRON), Canopy Growth Corporation (TSX: WEED) (OTC: TWMJF), Aphria, Inc. (TSX: APH) (OTCQB: APHQF) and Hiku Brands Company, Ltd. (CSE: HIKU) (OTC: DJACF) (DJACF Profile).

An Evolving Regulatory Landscape

Canada’s quest to become the first G7 nation to legalize recreational marijuana comes with a number of logistical and regulatory challenges (http://nnw.fm/zfk3U). Two of the most prominent in the nascent industry have related to licensing, both for growers and retailers. Canadian cultivators are currently subject to the Access to Cannabis for Medical Purposes Regulations (ACMPR). Implemented in 2016, the ACMPR places the administration of Canada’s cannabis cultivation industry in the hands of…

Read more »

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.

Tuesday, April 24th, 2018 Uncategorized Comments Off on $DJACF Early Regulations are Shaping the Future of Canadian Cannabis

$VSQTF Provides Investor Update on Strong Portfolio Performances

Investments in Bluzelle, Blockchain Assembly & FansUnite Highlighted

VANCOUVER, British Columbia, April 24, 2018 — Victory Square Technologies Inc. (“Victory Square” or the “Company”) (CSE:VST) (OTC:VSQTF) (FWB:6F6) is pleased to update investors on the strong performances by three of its portfolio companies.

Bluzelle Investment (511% INCREASE)

In December 2017, Victory Square purchased $250,000 Canadian worth of Bluzelle tokens (BLZ), with an additional 25% incentive bonus tokens received for being an early contributor. The Company’s average token price is $0.09 cents. As of April 22, 2018, BLZ trades for $0.55/token, representing a 511% increase over the average cost base.

Bluzelle is a decentralized database service where users are able to rent out their computer storage space and be compensated with a cryptocurrency token. Decentralized app developers then use these tokens to have their decentralized app’s data stored and managed. Decentralized database services have the potential to provide more scalable, secure and affordable storage solutions than current centralized alternatives.

VS Blockchain Assembly Inc. Financing ($12M GAIN)

The Company is excited to announce that VS Blockchain Assembly Inc. (“Blockchain Assembly”) recently completed a financing at $0.75 a share, valuing the company at approximately $33.2 million Canadian. Victory Square maintains an approximate 36.17% equity stake in Blockchain Assembly, which plans to list on the Canadian Securities Exchange later this year.

Incubated by Victory Square in 2017, Blockchain Assembly focuses on designing and deploying innovative token-based capital solutions for technology firms, while helping those businesses raise capital through comprehensive tokenization strategies that include delivering Token sales to the global capital markets.

FansUnite Media Inc. Acquisition (400% GAIN)

Victory Square acquired FansUnite Media Inc. (“FansUnite”) in September 2016 for $2 million Canadian in exchange for common shares in Victory Square. Victory Square is pleased to announce that FansUnite is currently raising a private placement round of $4 million Canadian (at a pre-money valuation of $13 million Canadian) towards their go-public strategy in Q4 2018. FansUnite is also planning to launch their regulatory-compliant token sale this summer to raise an additional $10 million Canadian of non-dilutive funding for the company.

FansUnite is using blockchain to disrupt the sports betting and sports data industries. The flagship FansUnite asset will be the first sports betting blockchain protocol, allowing any company to build their tokenized platform on top of the FansUnite infrastructure. The first application built atop this protocol will be the FansUnite Sportsbook, the first decentralized social sports betting platform in the world.

Overview

We have seen a number of other exceptional performances by Victory Square portfolio companies, including those by V2 Games Inc., Fantasy 360 Technologies Inc. doing business as Immersive Tech, Limitless Blockchain Technology, LLC, Cassia Research Inc., PayVida Solutions Inc., Flo Digital Inc., Howyl Ventures Inc., and Multiplied Networks Inc. Some of these investments have returned well in excess of 100% and have promising funding strategies that will be executed in 2018.

“We are delighted to report that we have seen extremely rapid growth amongst our portfolio companies as each one of them has achieved key milestones in the past few months,” commented Shafin Diamond Tejani, CEO of Victory Square. “The coming year is shaping up to be an exciting one, not only for our partner companies, but also for the overall development of the technology sector in Canada. As a result, our acquisition strategy and focus remains on finding quality companies in emerging technology verticals that have identified a sector niche and are in need of capital and expertise to scale out their operations.”

For further information about the Company, please contact:

Investor Relations Contact – Prit Singh
Email: prit@victorysquare.com
Telephone: 905-510-7636

Media Contact – Howard Blank, Director
Email: howard@victorysquare.com
Telephone: 604-928-6066

ABOUT VICTORY SQUARE TECHNOLOGIES INC.
Victory Square Technologies is a blockchain-focused venture builder that funds and empowers entrepreneurs to implement innovative blockchain solutions. Victory Square portfolio companies are disrupting every sector of the global economy including Virtual Reality, Artificial Intelligence, Personalized Health, Gaming and Film. Victory Square has a proven process for identifying game-changing entrepreneurs and providing them with the partners, mentorship and support necessary to accelerate their growth and help them scale globally. For more information, please visit www.victorysquare.com.

ABOUT THE CANADIAN SECURITIES EXCHANGE (CSE)
The Canadian Securities Exchange, or CSE, is operated by CNSX Markets Inc. Recognized as a stock exchange in 2004, the CSE began operations in 2003 to provide a modern and efficient alternative for companies looking to access the Canadian public capital markets.

FORWARD-LOOKING INFORMATION
This news release contains “forward-looking information” within the meaning of applicable securities laws relating to the outlook of the business of Victory Square, including, without limitation, statements relating to future performance by any portfolio company of the Company, the impact of any portfolio company’s performance on the Company, the strategic direction of the Company, and its goal of broadening its portfolio of interests in innovative companies. Such forward-looking statements may, without limitation, be preceded by, followed by, or include words such as “believes”, “expects”, “anticipates”, “estimates”, “intends”, “plans”, “continues”, “project”, “potential”, “possible”, “contemplate”, “seek”, “goal”, or similar expressions, or may employ such future or conditional verbs as “may”, “might”, “will”, “could”, “should” or “would”, or may otherwise be indicated as forward-looking statements by grammatical construction, phrasing or context. All statements other than statements of historical fact contained in this news release are forward-looking statements. Forward-looking information is based on certain key expectations and assumptions made by the management of Victory Square. Although Victory Square believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on them because Victory Square can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements contained in this news release are made as of the date of this news release. Victory Square disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Tuesday, April 24th, 2018 Uncategorized Comments Off on $VSQTF Provides Investor Update on Strong Portfolio Performances

$CIIX Establishes New Wholly Owned Foreign Enterprise

SAN GABRIEL, California, April 23, 2018 —

ChineseInvestors.com Inc. (OTCQB: CIIX)(“CIIX” or the “Company”), the premier financial information website for Chinese-speaking investors, today announces the expansion of its cryptocurrency and blockchain technology media and internet education business into China. In April 2018, the Company established a wholly owned foreign enterprise, NewCoins168.com Digital Media Technology Ltd (Shanghai), registered in China Free Trade Zone with registered capital of 10M RMB.

The Company’s United States counterpart http://www.newcoins168.com, established in November 2017, headquartered in New York City at 40 Wall Street in the Trump Building, currently staffs 5 editorial reporters. According to the Company’s CEO, Warren Wang, “In the coming year, we anticipate hiring 10-15 additional editors in Shanghai to work in conjunction with the New York and Los Angeles editors to provide 24/7 coverage of the latest global cryptocurrency and blockchain industry developments and trends.”

Most recently, the Company appointed Serena Ma as its new Editor-in-Chief in the New York office. Ma earned her Bachelor’s degree in journalism and economics in China and went on to obtain a Masters in journalism from Indiana University in 2012. Ma previously worked as Senior Editor for People’s Daily English in downtown Los Angeles, California.

“We are pleased that since its launch in 2018, http://www.newcoins168.com has become a well-known cryptocurrency and blockchain technology information portal among the North American Chinese community. We are looking forward to gaining popularity among the Chinese community worldwide and expanding into the China market,” says the Company’s CEO Warren Wang. “The Chinese website is intended to provide entry-level cryptocurrency and blockchain technology information. In addition, the Company plans to launch a mobile app that will provide timely, 24/7 news and analysis covering cryptocurrency and blockchain technology for the global Chinese community.”

About ChineseInvestors.com (OTCQB: CIIX)

Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail, online sales and direct sales of hemp-based products and other health related products.

For more information visit ChineseInvestors.com

Visit and register https ://www.newcoins168.com

Subscribe and watch our video commentaries: https://www.youtube.com/user/Chinesefncom

Subscribe and watch our video commentaries: https://www.youtube.com/channel/UCriTFjFHCvDW_LBhiIeuLlQ/featured

Follow us on Twitter for real-time Company updates: https://twitter.com/ChineseFNEnglsh

Like us on Facebook to receive live feeds: https://www.facebook.com/Chinesefncom

https://www.facebook.com/Chineseinvestors.com.english

Add us on WeChat: Chinesefn or download iPhone iOS App: Chinesefn.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Contact:
ChineseInvestors.com, Inc.
227 W. Valley Blvd, #208 A
San Gabriel, CA 91776

Investor Relations:
Alan Klitenic
+1-214-636-2548

Corporate Communications:
NetworkNewsWire (NNW)
New York, New York
http://www.NetworkNewsWire.com
+1-212-418-1217 Office
Editor@NetworkNewsWire.com

Tuesday, April 24th, 2018 Uncategorized Comments Off on $CIIX Establishes New Wholly Owned Foreign Enterprise